<DOC>
	<DOCNO>NCT02347865</DOCNO>
	<brief_summary>The purpose study describe characteristic management post menopausal woman osteoporosis treat Prolia France , examine use Prolia routine clinical practice France</brief_summary>
	<brief_title>Characteristics Management Postmenopausal Women With Osteoporosis Treated With Prolia® France</brief_title>
	<detailed_description>This multicenter , observational non-interventional study PMO patient receive Prolia® ( 60 mg subcutaneous [ SC ] ) France . Patients study enrol 2 wave , target specific aspect overall study objective . The first wave enroll approximately 500 patient follow approximately 30 month first injection . Patients enrol wave provide descriptive data persistence Prolia® well description characteristic patient prescribed Prolia® , information regard Prolia® prescription administration , procedure pertain Prolia® safety . The second wave enroll approximately 250 patient provide cross-sectional description characteristic patient prescribed Prolia . Around 2000 specialist rheumatology 9000 general practitioner randomly select list rheumatologists whether hospital private practice nationwide list general practitioner manage patient osteoporosis . In , 300 physician initially interested participate expect , 180 physician qualified participate . One-hundred ten physician initiate . There procedure change routine clinical management patient participate study . Baseline characteristic describe patient enrol wave 1 2 . Patients enrol wave 1 follow approximately 30 month date first injection study . It anticipate patient return site . Clinical information obtain routine clinical practice record available , include Prolia administration , previous current therapy , medical history ( include fracture ) , ADRs , SADRs co-morbidities.The study descriptive nature , formal hypothesis test . In general , data summary present wave subgroups interest .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>post menopausal osteoporosis woman decision make treat Prolia last 4 week receive first prescription Prolia last 4 week patient provide informed consent enrol study patient participate ongoing previous Denosumab clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>osteoporosis post menopausal woman</keyword>
</DOC>